Research
Parkinson's Disease and other movement disorders
Hope through research
The USF Health Byrd Parkinson's Disease & Movement Disorders Center evaluates and develops new medications and surgical procedures for Parkinson's Disease. Under Dr. Hauser's leadership, we conduct multiple independent and sponsored studies, pioneering advancements in treatment through research and innovation.
PPMI
Brief summary: Take the Smell Test Challenge Today! Smell loss can be linked to brain disease. Researchers are studying this link to learn more about the connection. Not everyone with smell loss will develop a brain disease. Request a scratch-and-sniff test to help scientists learn more about this risk factor.
Status: Recruiting (by cohort - contact our Center for details ) - To request a free smell test, visit:
Motric Bio
NCT06830642Brief summary: Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.
Status: Enrolling
https://clinicaltrials.gov/study/NCT06830642?lead=Motric%20Bio&rank=1
https://clinicaltrials.gov/study/NCT06830642?lead=Motric%20Bio&rank=1
Padova
ID: NCT04777331Brief summary: A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)
Status: Active, not recruiting
https://clinicaltrials.gov/study/NCT04777331?tab=results
M20-098
ID: NCT04750226Brief summary: Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Status: Maintaining
LUMA
ID: NCT05348785Brief summary: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)
Status: Maintaining
https://clinicaltrials.gov/study/NCT05348785
Pasadena
ID: NCT03100149Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline.
Status: Maintaining
Cerevance
CVN424-301Brief summary: A study to assess the efficacy of CVN424 dosed once daily, compared to placebo, for change in OFF time in Parkinson’s Disease.
Status: Enrolling
Truebinding
NCT06773962Brief summary: The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
Status: Enrolling
https://clinicaltrials.gov/study/NCT06773962
Support
Our clinical trials enable us to innovate and discover new, effective treatments for Parkinson's disease and other movement disorders. The importance of our work cannot be overstated, as it brings us closer to a cure and improves the quality of life for countless patients. Donations are crucial to sustaining this vital research and ensuring ongoing progress.
To support our mission, click here or reach out to Ashley Messer at amesser2@usf.edu or (813) 389-2845.
Truebinding
NCT06773962Brief summary: The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).
Status: Enrolling
https://clinicaltrials.gov/study/NCT06773962
Motric Bio
NCT06830642Brief summary: Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.
Status: Enrolling
https://clinicaltrials.gov/study/NCT06830642?lead=Motric%20Bio&rank=1
https://clinicaltrials.gov/study/NCT06830642?lead=Motric%20Bio&rank=1